Articles Published in 2011 Articles | CenterWatch News Online

Articles Published in 2011

Prev 10 21 22 23 24 25 26 27 28 29 30 Next 10

Connecticut approves $291 million funding for Jackson Laboratory

Wednesday, November 2, 2011 10:25 AM

The Connecticut legislature has approved $291 million in bond funding to build a new Jackson Laboratory center for personalized medicine and systems genomics in the state.

More... »

Intrexon acquires Immunologix

Wednesday, November 2, 2011 10:11 AM

Intrexon, a privately held synthetic biology company has acquired Immunologix. Immunologix specializes in transforming naïve B-cells to produce 100% human monoclonal antibodies that can target all antigen types including, but not limited to cancer cells, viruses, bacteria, toxins, plus those epitopes related to autoimmune diseases such as diabetes, lupus, rheumatoid arthritis and multiple sclerosis. Terms of the transaction were not disclosed.

More... »

Gemignani joins Champions Oncology

Wednesday, November 2, 2011 10:03 AM

Champions Oncology has named Gary G. Gemignani executive vice
president and chief financial officer.

More... »

Foundation Fighting Blindness invests $8.25 million in gene therapy research

Wednesday, November 2, 2011 09:43 AM

The Foundation Fighting Blindness, a national nonprofit dedicated to advancing sight-saving research, has reported an $8.25 million investment in six new gene therapy research projects that are targeted to have treatments ready for clinical trials within three years. The grants focus on treating a broad range of retinal degenerative diseases and will be allocated through the Foundation's Translational Research Acceleration Program, which funds research efforts with strong, near-term clinical potential.

More... »

The CenterWatch Monthly, November 2011

Tuesday, November 1, 2011 02:05 PM

CRAs see role evolving into quality, compliance, start-up

More... »

CGD report urges regional approach for safer, faster, cheaper clinical trials

Tuesday, November 1, 2011 12:22 PM

Scores of new medicines and other medical products to treat deadly diseases in poor countries are caught in a regulatory labyrinth that slows approvals, raises costs and sometimes puts patients at risk, according to a new report from the Center for Global Development.

More... »

FDA approves Roche’s hepatitis B test

Monday, October 31, 2011 12:51 PM

Roche has reported that the FDA granted Premarket Approval (PMA) for its IgM antibody to hepatitis B core antigen (Anti-HBc IgM) assay for use on the cobas e 601 analyzer, the immunoassay module of the cobas 6000 analyzer series for mid-volume laboratories. The test represents the final component of the acute panel within the hepatitis test menu for the cobas 6000 series.

More... »

AgonOx, MedImmune partner to develop cancer therapies

Monday, October 31, 2011 11:57 AM

AgonOx has entered into an exclusive global partnership with MedImmune, the global biologics arm of AstraZeneca, to develop agonists using its OX40 platform. MedImmune will lead further preclinical and clinical studies of this tumor-specific T-cell immunity stimulator for the potential treatment of cancer.

More... »

Revalesio’s first human asthma trial shows promising results

Monday, October 31, 2011 11:39 AM

Revalesio has reported that in this first in man asthma study, RNS60 demonstrated therapeutic benefit and proved safe at all dose levels. In a multi-dose stage of the phase I study, RNS60 significantly improved peak flows and quality of life scores in patients diagnosed with stable, mild to moderate asthma. These findings demonstrate that RNS60, a novel product containing charge-stabilized nanostructures (CSN), is safe and has therapeutic benefit in human subjects suffering from asthma.

More... »

Taylor joins Bestnet as senior scientist

Monday, October 31, 2011 11:14 AM

Bestnet has named Robert N. Taylor, Ph.D., senior scientist. In addition to a contributory role in the company's product research & development efforts, Taylor's activities will include participation in various scientific/technical working groups and representing Bestnet on scientific committees.

More... »